Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57

1.

Resistant Hypertension: Diagnosis and Management.

Nagarajan N, Jalal D.

Adv Chronic Kidney Dis. 2019 Mar;26(2):99-109. doi: 10.1053/j.ackd.2019.03.002. Review.

PMID:
31023454
2.

Evaluating the feasibility of a pharmacist-guided patient-driven intervention to improve blood pressure control in patients with CKD.

Hopley C, Andrews E, Klem P, Jonjak M, Grothe A, Ten Eyck P, You Z, Billups SJ, Lyon C, Kennelty K, Dixon B, Jalal D.

Pilot Feasibility Stud. 2019 Feb 12;5:23. doi: 10.1186/s40814-019-0410-0. eCollection 2019.

3.

Effects of Baseline Thrombocytopenia and Platelet Decrease Following Renal Replacement Therapy Initiation in Patients With Severe Acute Kidney Injury.

Griffin BR, Jovanovich A, You Z, Palevsky P, Faubel S, Jalal D.

Crit Care Med. 2019 Apr;47(4):e325-e331. doi: 10.1097/CCM.0000000000003598.

PMID:
30585829
4.

Examining the effects of uric acid-lowering on markers vascular of calcification and CKD-MBD; A post-hoc analysis of a randomized clinical trial.

Andrews ES, Perrenoud L, Nowak KL, You Z, Pasch A, Chonchol M, Kendrick J, Jalal D.

PLoS One. 2018 Oct 24;13(10):e0205831. doi: 10.1371/journal.pone.0205831. eCollection 2018.

5.

Light wine consumption is associated with a lower odd for cardiovascular disease in chronic kidney disease.

Jespersen T, Kruse N, Mehta T, Kuwabara M, Noureddine L, Jalal D.

Nutr Metab Cardiovasc Dis. 2018 Nov;28(11):1133-1139. doi: 10.1016/j.numecd.2018.06.018. Epub 2018 Aug 22.

PMID:
30143406
6.

Integrated safety studies of the urate reabsorption inhibitor lesinurad in treatment of gout.

Terkeltaub R, Saag KG, Goldfarb DS, Baumgartner S, Schechter BM, Valiyil R, Jalal D, Pillinger M, White WB.

Rheumatology (Oxford). 2019 Jan 1;58(1):61-69. doi: 10.1093/rheumatology/key245.

7.

Different Risk for Hypertension, Diabetes, Dyslipidemia, and Hyperuricemia According to Level of Body Mass Index in Japanese and American Subjects.

Kuwabara M, Kuwabara R, Niwa K, Hisatome I, Smits G, Roncal-Jimenez CA, MacLean PS, Yracheta JM, Ohno M, Lanaspa MA, Johnson RJ, Jalal DI.

Nutrients. 2018 Aug 3;10(8). pii: E1011. doi: 10.3390/nu10081011.

8.

Endothelial Microparticles and Systemic Complement Activation in Patients With Chronic Kidney Disease.

Jalal D, Renner B, Laskowski J, Stites E, Cooper J, Valente K, You Z, Perrenoud L, Le Quintrec M, Muhamed I, Christians U, Klawitter J, Lindorfer MA, Taylor RP, Holers VM, Thurman JM.

J Am Heart Assoc. 2018 Jul 13;7(14). pii: e007818. doi: 10.1161/JAHA.117.007818.

9.

Soluble Inflammatory Markers and Risk of Incident Fractures in Older Adults: The Cardiovascular Health Study.

Stojanović D, Bůžková P, Mukamal KJ, Heckbert SR, Psaty BM, Fink HA, Cauley JA, Wallace E, Curtis LH, Hirsch C, Budoff M, Li D, Young R, Jalal D, Delaney JA.

J Bone Miner Res. 2018 Feb;33(2):221-228. doi: 10.1002/jbmr.3301. Epub 2017 Nov 6.

10.

Higher plasma transforming growth factor (TGF)-β is associated with kidney disease in older community dwelling adults.

Mehta T, Buzkova P, Kizer JR, Djousse L, Chonchol M, Mukamal KJ, Shlipak M, Ix JH, Jalal D.

BMC Nephrol. 2017 Mar 21;18(1):98. doi: 10.1186/s12882-017-0509-6.

11.

Repair of Oxidative DNA Damage in Saccharomyces cerevisiae.

Chalissery J, Jalal D, Al-Natour Z, Hassan AH.

DNA Repair (Amst). 2017 Mar;51:2-13. doi: 10.1016/j.dnarep.2016.12.010. Epub 2017 Jan 28. Review.

PMID:
28189416
12.

The safety of achieved iron stores and their effect on IV iron and ESA use: post-hoc results from a randomized trial of ferric citrate as a phosphate binder in dialysis
.

Umanath K, Greco B, Jalal DI, McFadden M, Sika M, Koury MJ, Niecestro R, Hunsicker LG, Greene T, Lewis JB, Dwyer JP.

Clin Nephrol. 2017 Mar;87 (2017)(3):124-133. doi: 10.5414/CN108924.

PMID:
28128726
13.

Genome maintenance in Saccharomyces cerevisiae: the role of SUMO and SUMO-targeted ubiquitin ligases.

Jalal D, Chalissery J, Hassan AH.

Nucleic Acids Res. 2017 Mar 17;45(5):2242-2261. doi: 10.1093/nar/gkw1369. Review.

14.

Hyperuricemia, the kidneys, and the spectrum of associated diseases: a narrative review.

Jalal DI.

Curr Med Res Opin. 2016 Nov;32(11):1863-1869. Epub 2016 Aug 26. Review.

PMID:
27470664
15.

Vascular Function and Uric Acid-Lowering in Stage 3 CKD.

Jalal DI, Decker E, Perrenoud L, Nowak KL, Bispham N, Mehta T, Smits G, You Z, Seals D, Chonchol M, Johnson RJ.

J Am Soc Nephrol. 2017 Mar;28(3):943-952. doi: 10.1681/ASN.2016050521. Epub 2016 Sep 12.

16.

Adherence rates to ferric citrate as compared to active control in patients with end stage kidney disease on dialysis.

Jalal D, McFadden M, Dwyer JP, Umanath K, Aguilar E, Yagil Y, Greco B, Sika M, Lewis JB, Greene T, Goral S.

Hemodial Int. 2017 Apr;21(2):243-249. doi: 10.1111/hdi.12487. Epub 2016 Sep 12.

PMID:
27615161
17.

Systemic markers of microvascular disease and bone mineral density in older adults : The cardiovascular health study.

Barzilay JI, Bůžková P, Fink HA, Cauley JA, Robbins JA, Garimella PS, Jalal DI, Mukamal KJ.

Osteoporos Int. 2016 Nov;27(11):3217-3225. doi: 10.1007/s00198-016-3649-9. Epub 2016 Jun 1.

PMID:
27250972
18.

A Decline in Intraoperative Renal Near-Infrared Spectroscopy Is Associated With Adverse Outcomes in Children Following Cardiac Surgery.

Gist KM, Kaufman J, da Cruz EM, Friesen RH, Crumback SL, Linders M, Edelstein C, Altmann C, Palmer C, Jalal D, Faubel S.

Pediatr Crit Care Med. 2016 Apr;17(4):342-9. doi: 10.1097/PCC.0000000000000674.

19.

Soluble CD14 and fracture risk.

Bethel M, Bůžková P, Fink HA, Robbins JA, Cauley JA, Lee J, Barzilay JI, Jalal DI, Carbone LD.

Osteoporos Int. 2016 May;27(5):1755-63. doi: 10.1007/s00198-015-3439-9. Epub 2015 Dec 11.

20.

Complement Activation in Patients with Focal Segmental Glomerulosclerosis.

Thurman JM, Wong M, Renner B, Frazer-Abel A, Giclas PC, Joy MS, Jalal D, Radeva MK, Gassman J, Gipson DS, Kaskel F, Friedman A, Trachtman H.

PLoS One. 2015 Sep 3;10(9):e0136558. doi: 10.1371/journal.pone.0136558. eCollection 2015.

21.

A pilot study on the impact of a low fructose diet and allopurinol on clinic blood pressure among overweight and prehypertensive subjects: a randomized placebo controlled trial.

Madero M, Rodríguez Castellanos FE, Jalal D, Villalobos-Martín M, Salazar J, Vazquez-Rangel A, Johnson RJ, Sanchez-Lozada LG.

J Am Soc Hypertens. 2015 Nov;9(11):837-44. doi: 10.1016/j.jash.2015.07.008. Epub 2015 Jul 30.

PMID:
26329473
22.

Fructose and uric acid in diabetic nephropathy.

Bjornstad P, Lanaspa MA, Ishimoto T, Kosugi T, Kume S, Jalal D, Maahs DM, Snell-Bergeon JK, Johnson RJ, Nakagawa T.

Diabetologia. 2015 Sep;58(9):1993-2002. doi: 10.1007/s00125-015-3650-4. Epub 2015 Jun 7. Review.

23.

Ferric Citrate Reduces Intravenous Iron and Erythropoiesis-Stimulating Agent Use in ESRD.

Umanath K, Jalal DI, Greco BA, Umeukeje EM, Reisin E, Manley J, Zeig S, Negoi DG, Hiremath AN, Blumenthal SS, Sika M, Niecestro R, Koury MJ, Ma KN, Greene T, Lewis JB, Dwyer JP; Collaborative Study Group.

J Am Soc Nephrol. 2015 Oct;26(10):2578-87. doi: 10.1681/ASN.2014080842. Epub 2015 Mar 3.

24.

Association of Fetuin-A With Incident Fractures in Community-Dwelling Older Adults: The Cardiovascular Health Study.

Fink HA, Bůžková P, Garimella PS, Mukamal KJ, Cauley JA, Kizer JR, Barzilay JI, Jalal DI, Ix JH.

J Bone Miner Res. 2015 Aug;30(8):1394-402. doi: 10.1002/jbmr.2475. Epub 2015 May 21.

25.

Association of Uric Acid With Vascular Stiffness in the Framingham Heart Study.

Mehta T, Nuccio E, McFann K, Madero M, Sarnak MJ, Jalal D.

Am J Hypertens. 2015 Jul;28(7):877-83. doi: 10.1093/ajh/hpu253. Epub 2014 Dec 31.

26.

Serum urate levels and the risk of hip fractures: data from the Cardiovascular Health Study.

Mehta T, Bůžková P, Sarnak MJ, Chonchol M, Cauley JA, Wallace E, Fink HA, Robbins J, Jalal D.

Metabolism. 2015 Mar;64(3):438-46. doi: 10.1016/j.metabol.2014.11.006. Epub 2014 Nov 21.

27.

CKD and the interdisciplinary team: the logic behind the trend.

Jalal D, Weis B, Zuber K, Davis J.

Adv Chronic Kidney Dis. 2014 Jul;21(4):331-2. doi: 10.1053/j.ackd.2014.05.003. No abstract available.

PMID:
24969382
28.

Assessment of vascular function in patients with chronic kidney disease.

Jablonski KL, Decker E, Perrenoud L, Kendrick J, Chonchol M, Seals DR, Jalal D.

J Vis Exp. 2014 Jun 16;(88). doi: 10.3791/51478.

29.

Serum uric acid and hypertension in adults: a paradoxical relationship in type 1 diabetes.

Bjornstad P, Paul Wadwa R, Sirota JC, Snell-Bergeon JK, McFann K, Rewers M, Rivard CJ, Jalal D, Chonchol MB, Johnson RJ, Maahs DM.

J Clin Hypertens (Greenwich). 2014 Apr;16(4):283-8. doi: 10.1111/jch.12305. Epub 2014 Mar 26.

30.

Serum uric acid and insulin sensitivity in adolescents and adults with and without type 1 diabetes.

Bjornstad P, Snell-Bergeon JK, McFann K, Wadwa RP, Rewers M, Rivard CJ, Jalal D, Chonchol MB, Johnson RJ, Maahs DM.

J Diabetes Complications. 2014 May-Jun;28(3):298-304. doi: 10.1016/j.jdiacomp.2013.12.007. Epub 2013 Dec 27.

31.

Uric acid suppresses 1 alpha hydroxylase in vitro and in vivo.

Chen W, Roncal-Jimenez C, Lanaspa M, Gerard S, Chonchol M, Johnson RJ, Jalal D.

Metabolism. 2014 Jan;63(1):150-60. doi: 10.1016/j.metabol.2013.09.018. Epub 2013 Oct 23.

32.

Early diabetic nephropathy: a complication of reduced insulin sensitivity in type 1 diabetes.

Bjornstad P, Snell-Bergeon JK, Rewers M, Jalal D, Chonchol MB, Johnson RJ, Maahs DM.

Diabetes Care. 2013 Nov;36(11):3678-83. doi: 10.2337/dc13-0631. Epub 2013 Sep 11.

33.

Impaired renal function further increases odds of 6-year coronary artery calcification progression in adults with type 1 diabetes: the CACTI study.

Maahs DM, Jalal D, Chonchol M, Johnson RJ, Rewers M, Snell-Bergeon JK.

Diabetes Care. 2013 Sep;36(9):2607-14. doi: 10.2337/dc12-2538. Epub 2013 Jul 8.

34.

Uric acid lowering to prevent kidney function loss in diabetes: the preventing early renal function loss (PERL) allopurinol study.

Maahs DM, Caramori L, Cherney DZ, Galecki AT, Gao C, Jalal D, Perkins BA, Pop-Busui R, Rossing P, Mauer M, Doria A; PERL Consortium.

Curr Diab Rep. 2013 Aug;13(4):550-9. doi: 10.1007/s11892-013-0381-0. Review.

35.

Uric acid and chronic kidney disease: which is chasing which?

Johnson RJ, Nakagawa T, Jalal D, Sánchez-Lozada LG, Kang DH, Ritz E.

Nephrol Dial Transplant. 2013 Sep;28(9):2221-8. doi: 10.1093/ndt/gft029. Epub 2013 Mar 29. Review.

36.

Uric acid and the origins of hypertension.

Feig DI, Madero M, Jalal DI, Sanchez-Lozada LG, Johnson RJ.

J Pediatr. 2013 May;162(5):896-902. doi: 10.1016/j.jpeds.2012.12.078. Epub 2013 Feb 10. Review. No abstract available.

PMID:
23403249
37.

Association between nonalcoholic liver disease and chronic kidney disease: an ultrasound analysis from NHANES 1988-1994.

Sirota JC, McFann K, Targher G, Chonchol M, Jalal DI.

Am J Nephrol. 2012;36(5):466-71. doi: 10.1159/000343885. Epub 2012 Nov 2.

38.

Uric acid as a target of therapy in CKD.

Jalal DI, Chonchol M, Chen W, Targher G.

Am J Kidney Dis. 2013 Jan;61(1):134-46. doi: 10.1053/j.ajkd.2012.07.021. Epub 2012 Oct 9. Review.

39.
40.

Vascular endothelial function is not related to serum uric acid in healthy adults.

Jalal DI, Jablonski KL, McFann K, Chonchol MB, Seals DR.

Am J Hypertens. 2012 Apr;25(4):407-13. doi: 10.1038/ajh.2011.237. Epub 2012 Jan 12.

41.

Clinical outcome of hyperuricemia in IgA nephropathy: a retrospective cohort study and randomized controlled trial.

Shi Y, Chen W, Jalal D, Li Z, Chen W, Mao H, Yang Q, Johnson RJ, Yu X.

Kidney Blood Press Res. 2012;35(3):153-60. doi: 10.1159/000331453. Epub 2011 Nov 23.

42.

C-reactive protein as a predictor of cardiovascular events in elderly patients with chronic kidney disease.

Jalal D, Chonchol M, Etgen T, Sander D.

J Nephrol. 2012 Sep-Oct;25(5):719-25. doi: 10.5301/jn.5000047.

43.

Uric acid as a mediator of diabetic nephropathy.

Jalal DI, Maahs DM, Hovind P, Nakagawa T.

Semin Nephrol. 2011 Sep;31(5):459-65. doi: 10.1016/j.semnephrol.2011.08.011. Review.

44.

Age and sex influence cystatin C in adolescents with and without type 1 diabetes.

Maahs DM, Prentice N, McFann K, Snell-Bergeon JK, Jalal D, Bishop FK, Aragon B, Wadwa RP.

Diabetes Care. 2011 Nov;34(11):2360-2. doi: 10.2337/dc11-0829. Epub 2011 Sep 16.

45.

Systematic shifts in cystatin C between 2006 and 2010.

Maahs DM, Jalal D, McFann K, Rewers M, Snell-Bergeon JK.

Clin J Am Soc Nephrol. 2011 Aug;6(8):1952-5. doi: 10.2215/CJN.11271210. Epub 2011 Jul 22.

46.

The effect of two energy-restricted diets, a low-fructose diet versus a moderate natural fructose diet, on weight loss and metabolic syndrome parameters: a randomized controlled trial.

Madero M, Arriaga JC, Jalal D, Rivard C, McFann K, Pérez-Méndez O, Vázquez A, Ruiz A, Lanaspa MA, Jimenez CR, Johnson RJ, Lozada LG.

Metabolism. 2011 Nov;60(11):1551-9. doi: 10.1016/j.metabol.2011.04.001. Epub 2011 May 31.

PMID:
21621801
47.

Sucrose induces fatty liver and pancreatic inflammation in male breeder rats independent of excess energy intake.

Roncal-Jimenez CA, Lanaspa MA, Rivard CJ, Nakagawa T, Sanchez-Lozada LG, Jalal D, Andres-Hernando A, Tanabe K, Madero M, Li N, Cicerchi C, Mc Fann K, Sautin YY, Johnson RJ.

Metabolism. 2011 Sep;60(9):1259-70. doi: 10.1016/j.metabol.2011.01.008. Epub 2011 Apr 12.

48.

Serum uric acid level and endothelial dysfunction in patients with nondiabetic chronic kidney disease.

Kanbay M, Yilmaz MI, Sonmez A, Turgut F, Saglam M, Cakir E, Yenicesu M, Covic A, Jalal D, Johnson RJ.

Am J Nephrol. 2011;33(4):298-304. doi: 10.1159/000324847. Epub 2011 Mar 8.

49.

Dietary fructose and hypertension.

Madero M, Perez-Pozo SE, Jalal D, Johnson RJ, Sánchez-Lozada LG.

Curr Hypertens Rep. 2011 Feb;13(1):29-35. doi: 10.1007/s11906-010-0163-x. Review.

PMID:
20957458
50.

Serum uric acid predicts progression of subclinical coronary atherosclerosis in individuals without renal disease.

Rodrigues TC, Maahs DM, Johnson RJ, Jalal DI, Kinney GL, Rivard C, Rewers M, Snell-Bergeon JK.

Diabetes Care. 2010 Nov;33(11):2471-3. doi: 10.2337/dc10-1007. Epub 2010 Aug 26.

Supplemental Content

Support Center